Company profile for Abata Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Abata Therapeutics is a biotech company focused on translating the biology of regulatory T cells (Tregs) into transformational medicine.We are bringing an entirely new approach to the treatment of autoimmune disease by engineering Tregs as targeted therapies that stop immune-mediated destruction, restore homeostasis – a state of harmony – and promote repair in the affected tissues. In addition to our lead program in progre...
Abata Therapeutics is a biotech company focused on translating the biology of regulatory T cells (Tregs) into transformational medicine.We are bringing an entirely new approach to the treatment of autoimmune disease by engineering Tregs as targeted therapies that stop immune-mediated destruction, restore homeostasis – a state of harmony – and promote repair in the affected tissues. In addition to our lead program in progressive MS, Abata has early programs in Type 1 Diabetes (T1D) and inclusion body myositis (IBM). We bring together industry experts and deeply engaged pioneers in Treg biology, T cell receptor and antigen discovery

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Cambridge, MA US
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Clinical Outsourcing

Clinical Outsourcing

Not Confirmed

envelop Contact Supplier

Clinical Outsourcing

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2024/09/16/2946472/0/en/Abata-Therapeutics-Appoints-Joanne-Beck-Ph-D-as-Chief-Technical-Officer.html

GLOBENEWSWIRE
16 Sep 2024

https://www.globenewswire.com/news-release/2024/08/22/2934105/0/en/Abata-Therapeutics-Receives-FDA-Fast-Track-Designation-for-ABA-101-for-the-Treatment-of-Progressive-Multiple-Sclerosis.html

GLOBENEWSWIRE
22 Aug 2024

https://www.globenewswire.com/news-release/2024/08/15/2930788/0/en/Abata-Therapeutics-Announces-Strategic-Investment-from-Bristol-Myers-Squibb-Supporting-Advancement-of-its-Treg-Cell-Therapy-Pipeline-into-Clinical-Development.html

GLOBENEWSWIRE
15 Aug 2024

https://www.globenewswire.com/en/news-release/2024/07/09/2910147/0/en/Abata-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-Clinical-Evaluation-of-ABA-101-in-Progressive-Multiple-Sclerosis.html

GLOBENEWSWIRE
09 Jul 2024

https://www.businesswire.com/news/home/20230824945846/en

BUSINESSWIRE
24 Aug 2023

https://www.businesswire.com/news/home/20230531005339/en

BUSINESSWIRE
31 May 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty